Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi ( (SNY) ) has shared an announcement.
In September 2025, Sanofi announced significant advancements in their product offerings. On September 10, 2025, Tzield was approved in China as the first disease-modifying therapy for stage 2 type 1 diabetes, marking a new era in diabetes care by delaying the onset of stage 3 T1D. This approval aligns with Chinese guidelines emphasizing the protection of beta-cell function. Additionally, on September 11, 2025, Sanofi’s SAR402663 received fast track designation in the US for treating neovascular age-related macular degeneration, enhancing their position in the ophthalmology sector. Furthermore, on September 17, 2025, Sanofi reported positive phase 2a study results for brivekimig in treating hidradenitis suppurativa, underscoring their commitment to addressing unmet medical needs.
The most recent analyst rating on (SNY) stock is a Buy with a $58.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
Sanofi’s overall stock score is driven by its strong earnings call performance and attractive valuation, which are offset by bearish technical indicators and moderate financial performance. The company’s strategic initiatives and positive sales outlook contribute significantly to its score, despite some challenges in cash flow and market momentum.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D driven, AI-powered biopharma company dedicated to improving lives and fostering growth through innovative medicines and vaccines. They focus on leveraging their deep understanding of the immune system to address urgent healthcare challenges globally. Sanofi is listed on EURONEXT and NASDAQ.
Average Trading Volume: 2,508,917
Technical Sentiment Signal: Hold
Current Market Cap: $114.1B
Learn more about SNY stock on TipRanks’ Stock Analysis page.